TICKERNERD
Menu
BNTCBNTCHealthcare · Biotechnology

BNTC Stock Forecast: Benitec Biopharma, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$8.83
+0.34% on the day

The 8 Wall Street analysts covering Benitec Biopharma, Inc. hold a median 12-month price target of $24 — +171.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$302.8M
Ticker Nerd rank
38/ 100
Median analyst target
$24
Analysts covering
8
Revenue$0.0
Operating income−$13.6M
Net income−$11.9M
Free cash flow−$4.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.1%
1M
−9.4%
YTD
−34.4%
1Y
−45.4%
From 52W high
−46.0%
From 52W low
+8.9%
$8
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BNTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Benitec Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
38/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
84
Quality
75
Accruals
73
Size
61
Value
47
Revisions
32
Issuance
30
Growth
27
Momentum
20

Volatility (84): The share price has been relatively steady.

Momentum (20): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BNTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BNTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26BNTCHigh $32Median $24Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $14Median $24High $32

The green dot is the last close — the median target sits +171.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Oct 2026Raymond JamesInitiatesOutperform$14
15 Sept 2026WedbushMaintainsOutperform$16 → $17
15 Sept 2026WedbushMaintainsOutperform—
28 July 2026WedbushInitiatesOutperform$16
28 July 2026WedbushInitiatesOutperform—
12 May 2026Evercore ISI GroupInitiatesOutperform$25
12 May 2026Evercore ISI GroupInitiatesOutperform—
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
4 Nov 2025CitizensMaintainsMarket Outperform—
4 Nov 2025HC Wainwright & Co.MaintainsBuy—
24 Sept 2025JMP SecuritiesReiteratesMarket Outperform—
16 Sept 2025OppenheimerMaintainsOutperform—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
15 May 2025JMP SecuritiesReiteratesMarket Outperform—
10 Apr 2025JMP SecuritiesMaintainsMarket Outperform—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
21 Feb 2025HC Wainwright & Co.ReiteratesBuy—
13 Dec 2024BairdInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BNTC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BNTC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Benitec Biopharma, Inc. returned −45.4% against +13.1% for the S&P 500, dividends included.

BNTC vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26BNTCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BNTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Benitec Biopharma, Inc. (BNTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.0×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
1.7×

Cheaper than 49% of US stocks

EV / EBITDA
−2.4×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−33.2%

Higher than 26% of US stocks

Return on assets
−22.7%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Benitec Biopharma, Inc. (BNTC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Benitec Biopharma, Inc. has a market value of $302.8M and an enterprise value of $123.6M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$48.9M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$19.8M.

  • Shares outstanding: 34.4M.

  • Trailing P/E: −8.0×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Benitec Biopharma, Inc. employs 24 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

BNTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BNTCBenitec Biopharma, Inc.$302.8M38
IRDOpus Genetics, Inc.$299.5M55
EIKNEikon Therapeutics, Inc.$299.7M1
SABSSAB Biotherapeutics, Inc.$291.2M41
FULCFulcrum Therapeutics, Inc.$286.1M44
VOGXVogenx, Inc.$281.1M1
RCKTRocket Pharmaceuticals, Inc.$279.2M53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Benitec Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BNTC news & analysis

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

GlobeNewsWire · 28 Oct 2026positive

Benitec Biopharma reported positive interim Phase 1b/2a results for high-dose BB-301 and continued durable improvements with the low dose in patients with OPMD-related swallowing difficulties. The company said all patients treated across both doses were formal responders, with high-dose patients showing greater relative improvements at three months in throat emptying and functional swallowing capacity.

Why it matters — The interim findings provide an update on BB-301’s clinical performance across both doses in the ongoing first-in-human study.

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

GlobeNewsWire · 5 Oct 2026neutral

Benitec Biopharma announced it received formal FDA feedback following its third-quarter 2026 Type C meeting regarding the BB-301 pivotal study. The FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study, and the final pivotal study design is expected to be confirmed in the first quarter of 2027, with the trial still on track to start mid-2027. Benitec will also present interim clinical results from its ongoing BB-301 Phase 1b/2a study at the ESGCT Annual Congress in Hamburg in October 2026.

Why it matters — This update provides BNTC watchers with clarity on the regulatory timeline and expected design confirmation for the pivotal BB-301 trial, as well as upcoming interim clinical data presentations.

After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)

Zacks Investment Research · 25 Sept 2026positive

Benitec Biopharma's stock is in technically oversold territory after falling 23.9% over four weeks, and heavy selling pressure may be exhausted. Strong agreement among Wall Street analysts in raising earnings estimates could support a trend reversal for the stock.

Why it matters — A potential trend reversal after oversold conditions and analyst estimate upgrades could be relevant for BNTC watchers tracking the stock's near-term direction.

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

GlobeNewsWire · 14 Sept 2026positive

Benitec Biopharma released full year 2026 financial results and an operational update. All six Cohort 1 (low dose BB-301) patients completed the 12-month post-treatment follow-up, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients safely treated. A Type C meeting with the FDA was held in 3Q2026 to discuss the BB-301 pivotal study design, with meeting minutes anticipated in October. Additional interim results were accepted for a late-breaking presentation at the ESGCT Annual Congress in Hamburg (October 27-30, 2026). Cash as of June 30, 2026 was approximately $180 million.

Why it matters — A BNTC watcher would care because the update signals clinical progress on BB-301, regulatory engagement with the FDA on the pivotal study design, and a substantial cash position funding ongoing operations.

FAQ

Frequently asked questions about BNTC stock

What is the BNTC stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Benitec Biopharma, Inc. have a median 12-month price target of $24, with estimates ranging from $14 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BNTC stock a buy right now?

Of the 8 analysts covering Benitec Biopharma, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Benitec Biopharma, Inc. 38 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BNTC?

As at 28 Oct 2026, Benitec Biopharma, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).

Will BNTC stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +171.8% from the last close, and Ticker Nerd's factor model ranks Benitec Biopharma, Inc. 38 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BNTC stock forecast for 2030?

No analyst covering Benitec Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BNTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $32 over the next 12 months.

How has BNTC stock performed over the past year?

Benitec Biopharma, Inc. returned -45.4% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Benitec Biopharma, Inc. do?

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary Silence and Replace platform.

What is the latest news on BNTC?

The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301". Benitec Biopharma reported positive interim Phase 1b/2a results for high-dose BB-301 and continued durable improvements with the low dose in patients with OPMD-related swallowing difficulties. The company said all patients treated across both doses were formal responders, with high-dose patients showing greater relative improvements at three months in throat emptying and functional swallowing capacity.

Company

About Benitec Biopharma, Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary Silence and Replace platform. The company combines RNA interference with gene therapy to create treatments designed to silence disease-causing genes while also delivering functional gene replacement in a single administration. Its current work centers on ddRNAi-based therapeutics for chronic and life-threatening conditions, with a particular emphasis on rare genetic disorders such as oculopharyngeal muscular dystrophy. Benitec Biopharma’s pipeline reflects a precision medicine approach aimed at addressing unmet needs in genetic disease through targeted, durable molecular intervention. Headquartered in Hayward, California, Benitec Biopharma Inc. operates in the biotechnology and gene therapy sectors, where it contributes to the development of advanced platform-based therapies for difficult-to-treat human diseases.

CEO Dr. Jerel A. Banks M.D., Ph.D. · 24 employees · United States · https://benitec.com